Seroprevalence of sars-cov-2 antibodies in symptomatic individuals is higher than in persons who are at increased risk exposure: The results of the single-center, prospective, cross-sectional study › Research Explorer

Seroprevalence of sars-cov-2 antibodies in symptomatic individuals is higher than in persons who are at increased risk exposure: The results of the single-center, prospective, cross-sectional study

Research output: Contribution to journal › Article › peer-review

Institute of Natural Sciences and Mathematics

DOI

https://doi.org/10.3390/vaccines9060627
Final published version

A. Zurochka
M. Dobrinina
V. Zurochka
D. Hu
A. Solovyev
L. Ryabova
Igor Kritsky
Roman Ibragimov
Alexey Sarapultsev

Original language	English
Article number	627
Number of pages	12
Journal	Vaccines
Volume	9
Issue number	6
DOIs	https://doi.org/10.3390/vaccines9060627
Publication status	Published - Jun 2021

Research areas

Antibody, COVID-19, Focus groups, Global health, High-risk groups, Seroprevalence, global health, POPULATION, IMMUNITY, antibody, seroprevalence, IGG, RESPONSES, high-risk groups, focus groups, INFECTION, SEX-DIFFERENCES

WoS ResearchAreas Categories

Immunology
Medicine, Research & Experimental

ASJC Scopus subject areas

Drug Discovery
Infectious Diseases
Pharmacology (medical)
Pharmacology
Immunology

ID: 22222119